Psycho-Babble Medication | about biological treatments | Framed
This thread | Show all | Post follow-up | Start new thread | List of forums | Search | FAQ

Reclast for Osteoporosis New Doses Much Lower

Posted by Phillipa on June 8, 2011, at 23:58:47

Oh wow so glad didn't get the 5mg of reclast two years ago as now latest studies show benefits and reduced signicantly side effects which caused death in some per another osteo website I frequent. This sounds encouraging for all us females!!!!Reclast is brand name. Below generic but same. Phillipa

Medscape Medical News from:
ENDO 2011: The Endocrine Society 93rd Annual Meeting

This coverage is not sanctioned by, nor a part of, The Endocrine Society.

From Medscape Medical News
Lower Annual Doses of Zoledronate May Do the Trick
Megan Brooks

Authors and Disclosures
June 7, 2011 (Boston, Massachusetts) Lower doses than are currently prescribed of the bisphosphonate zoledronate may be enough to increase bone density and reduce bone resorption in postmenopausal women, according to a randomized controlled study reported here at ENDO 2011: The Endocrine Society 93rd Annual Meeting.

"Our research suggests that one fifth or one half of the recommended dose might be sufficient to decrease fracture risk," said presenter and principal investigator Andrew Grey, MD, from the University of Auckland in New Zealand.

"If that is so, it would reduce the healthcare costs of treating osteoporosis and may reduce the likelihood of side effects of the medication," he added.

Optimal Zoledronate Dose Unclear

Zoledronate is widely used for the treatment of osteoporosis. It is currently prescribed as a once-yearly infusion of 5.0 mg. This regimen is "pretty effective," Dr. Grey said. "It reduces the risk of fragility fractures in postmenopausal women with osteoporosis by between 35% and 70%, depending on the skeletal site." It also decreases the risk of dying after hip fracture by 28%.

However, the optimal dosing schedule of zoledronate remains unclear. In an early phase 2 trial, annual doses ranging from 1 to 4 mg given in different frequencies were equally effective in reducing markers of bone turnover and increasing bone density.

To investigate further, Dr. Grey's team randomly allocated 180 osteopenic postmenopausal women to a single dose of placebo or to 1.0 mg, 2.5 mg, or 5.0 mg of intravenous zoledronate.

After 12 months, change in spine and hip bone mineral density (BMD) was significantly greater in each of the zoledronate groups than in the placebo group (P < .001).

Change in BMD by Zoledronate Dose, Compared With Placebo

Outcome 1.0 mg (95% CI) 2.5 mg (95% CI) 5.0 mg (95% CI)
Spine BMD 3.5% (2.24.8) 4.0% (2.75.3) 3.6% (2.34.9)
Hip BMD 2.7% (1.93.5) 3.6% (2.84.4) 3.6% (2.84.4)
CI, confidence interval


In addition, all doses of zoledronate were significantly more effective than placebo in decreasing levels of 2 bone turnover markers beta C-terminal telopeptide (beta-CTx) and procollagen 1 N-terminal peptide (P1NP). Each of these markers were "stably decreased between 6 and 12 months," Dr. Grey and colleagues note in a meeting abstract. Acute-phase reaction tended to occur less often in the 1 mg group than in either of the higher-dose groups.

Significant Cost Implications

These data demonstrate that the annual administration of 1.0 mg or 2.5 mg of zoledronate produces substantial antiresorptive effects and increases in BMD that approximate those of the 5.0 mg dose, "suggesting that these lower doses may prevent fractures," Dr. Grey said. "This study wasn't big enough to determine whether that is the case, but it certainly is very suggestive."

"Clinical trials should be undertaken to determine the ability of low doses of zoledronate to prevent fractures," Dr. Grey added.

Henry Anhalt, DO, from St. Barnabas Medical Center in Livingstone, New Jersey, who moderated the press briefing during which the data were released, said this is one of the studies being presented here at ENDO 2011 that could have "broad-reaching implications" by affecting "health economics and healthcare costs, which are becoming increasing more important."

It might also lead to "improved quality of life in postmenopausal women," he added.

The study was supported by the Health Research Council of New Zealand. Dr. Grey and Dr. Anhalt have disclosed no relevant financial relationships.

ENDO 2011: The Endocrine Society 93rd Annual Meeting. Abstract OR29-3. Presented June 6, 2011.

 

Thread

 

Post a new follow-up

Your message only Include above post


[987531]

Notify the administrators

They will then review this post with the posting guidelines in mind.

To contact them about something other than this post, please use this form instead.

 

Start a new thread

 
Google
dr-bob.org www
Search options and examples
[amazon] for
in

This thread | Show all | Post follow-up | Start new thread | FAQ
Psycho-Babble Medication | Framed

poster:Phillipa thread:987531
URL: http://www.dr-bob.org/babble/20110529/msgs/987531.html